OpenAI’s Sam Altman is becoming one of the most powerful people on Earth. We should be very afraid
By Gary Marcus,
The Guardian
| 08. 03. 2024
Image by TechCrunch from Flickr licensed under CC by 2.0
On 16 May 2023, Sam Altman, OpenAI’s charming, softly spoken, eternally optimistic billionaire CEO, and I stood in front of the US Senate judiciary subcommittee meeting on AI oversight. We were in Washington DC, and it was at the height of AI mania. Altman, then 38, was the poster boy for it all.
Raised in St Louis, Missouri, Altman was the Stanford dropout who had become the president of the massively successful Y Combinator startup incubator before he was 30. A few months before the hearing, his company’s product ChatGPT had taken the world by storm. All through the summer of 2023, Altman was treated like a Beatle, stopping by DC as part of a world tour, meeting prime ministers and presidents around the globe. US Senator Kyrsten Sinema gushed: “I’ve never met anyone as smart as Sam… He’s an introvert and shy and humble… But… very good at forming relationships with people on the Hill and… can help folks in government understand AI.” Glowing portraits at the...
Related Articles
By Harry Hunter, PET BioNews | 08.11.2025
The Parliamentary Office of Science and Technology has announced plans to publish a POSTnote and called for submissions on surrogacy law in the UK and internationally.
The current UK surrogacy laws, largely based on legislation from the 1980s, have been...
By Sayantani DasGupta, MedPage Today | 08.05.2025
It's just a jeans ad.
It's not that deep.
It's just social media outrage.
Should physicians care about the recent American Eagle "Sydney Sweeney Has Good Genes Jeans" controversy? What, if anything, does the provocative campaign have to...
By Zusha Elinson, The Wall Street Journal | 08.12.2025
BERKELEY, Calif.—Tsvi Benson-Tilsen, a mathematician, spent seven years researching how to keep an advanced form of artificial intelligence from destroying humanity before he concluded that stopping it wasn’t possible—at least anytime soon.
Now, he’s turned his considerable brainpower to promoting...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...